drugset / Trial / NCT06898385
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
Timeline
- Start
- 2025-03-27
- Primary completion
- 2027-03-27
- Completion
- 2027-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IX001 TCR-T injection | Cell therapy | 3e+09 cells | Intravenous |
| Subject | IX001 TCR-T injection | Cell therapy | 1e+10 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |